448 related articles for article (PubMed ID: 27862160)
1. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
Mamidi RNVS; Dallas S; Sensenhauser C; Lim HK; Scheers E; Verboven P; Cuyckens F; Leclercq L; Evans DC; Kelley MF; Johnson MD; Snoeys J
Br J Clin Pharmacol; 2017 May; 83(5):1082-1096. PubMed ID: 27862160
[TBL] [Abstract][Full Text] [Related]
2. In Vitro Interaction of AB-FUBINACA with Human Cytochrome P450, UDP-Glucuronosyltransferase Enzymes and Drug Transporters.
Kim S; Kim DK; Shin Y; Jeon JH; Song IS; Lee HS
Molecules; 2020 Oct; 25(19):. PubMed ID: 33050066
[TBL] [Abstract][Full Text] [Related]
3. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
5. Physiologically Based Pharmacokinetic Models for Prediction of Complex CYP2C8 and OATP1B1 (SLCO1B1) Drug-Drug-Gene Interactions: A Modeling Network of Gemfibrozil, Repaglinide, Pioglitazone, Rifampicin, Clarithromycin and Itraconazole.
Türk D; Hanke N; Wolf S; Frechen S; Eissing T; Wendl T; Schwab M; Lehr T
Clin Pharmacokinet; 2019 Dec; 58(12):1595-1607. PubMed ID: 31129789
[TBL] [Abstract][Full Text] [Related]
6. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
[TBL] [Abstract][Full Text] [Related]
7. An Assessment of the In Vitro Inhibition of Cytochrome P450 Enzymes, UDP-Glucuronosyltransferases, and Transporters by Phosphodiester- or Phosphorothioate-Linked Oligonucleotides.
Kazmi F; Yerino P; McCoy C; Parkinson A; Buckley DB; Ogilvie BW
Drug Metab Dispos; 2018 Aug; 46(8):1066-1074. PubMed ID: 29735754
[TBL] [Abstract][Full Text] [Related]
8. In Vitro Assessment of the Drug-Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters.
Gopaul VS; Vildhede A; Andersson TB; Erlandsson F; Lee CA; Johansson S; Hilgendorf C
J Pharmacol Exp Ther; 2021 Aug; 378(2):108-123. PubMed ID: 34074714
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
10. Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions.
Hanke N; Gómez-Mantilla JD; Ishiguro N; Stopfer P; Nock V
Pharm Res; 2021 Oct; 38(10):1645-1661. PubMed ID: 34664206
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the Drug Interaction Potential of Unconjugated and GalNAc
Shemesh CS; Yu RZ; Warren MS; Liu M; Jahic M; Nichols B; Post N; Lin S; Norris DA; Hurh E; Huang J; Watanabe T; Henry SP; Wang Y
Mol Ther Nucleic Acids; 2017 Dec; 9():34-47. PubMed ID: 29246313
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.
Kim SJ; Toshimoto K; Yao Y; Yoshikado T; Sugiyama Y
J Pharm Sci; 2017 Sep; 106(9):2715-2726. PubMed ID: 28479356
[TBL] [Abstract][Full Text] [Related]
13. Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Umehara K; Huth F; Jin Y; Schiller H; Aslanis V; Heimbach T; He H
Drug Metab Pers Ther; 2019 May; 34(2):. PubMed ID: 31145690
[TBL] [Abstract][Full Text] [Related]
14. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction.
Bolleddula J; Ke A; Yang H; Prakash C
CPT Pharmacometrics Syst Pharmacol; 2021 Jun; 10(6):577-588. PubMed ID: 33822485
[TBL] [Abstract][Full Text] [Related]
15. Assessment of interaction potential of AZD2066 using in vitro metabolism tools, physiologically based pharmacokinetic modelling and in vivo cocktail data.
Nordmark A; Andersson A; Baranczewski P; Wanag E; Ståhle L
Eur J Clin Pharmacol; 2014 Feb; 70(2):167-78. PubMed ID: 24186263
[TBL] [Abstract][Full Text] [Related]
16. A physiologically based pharmacokinetic (PBPK) parent-metabolite model of the chemotherapeutic zoptarelin doxorubicin-integration of in vitro results, Phase I and Phase II data and model application for drug-drug interaction potential analysis.
Hanke N; Teifel M; Moj D; Wojtyniak JG; Britz H; Aicher B; Sindermann H; Ammer N; Lehr T
Cancer Chemother Pharmacol; 2018 Feb; 81(2):291-304. PubMed ID: 29204687
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.
Chino Y; Hasegawa M; Fukasawa Y; Mano Y; Bando K; Miyata A; Nakai Y; Endo H; Yamaguchi JI
Xenobiotica; 2017 Apr; 47(4):314-323. PubMed ID: 27324291
[TBL] [Abstract][Full Text] [Related]
18. Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.
Varma MV; Lai Y; Kimoto E; Goosen TC; El-Kattan AF; Kumar V
Pharm Res; 2013 Apr; 30(4):1188-99. PubMed ID: 23307347
[TBL] [Abstract][Full Text] [Related]
19. In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes.
Chen N; Cui D; Wang Q; Wen Z; Finkelman RD; Welty D
Xenobiotica; 2018 Jun; 48(6):637-646. PubMed ID: 28730856
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Inhibitory Effects of APINACA on Human Major Cytochrome P450, UDP-Glucuronosyltransferase Enzymes, and Drug Transporters.
Kim S; Choi WG; Kwon M; Lee S; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
Molecules; 2019 Aug; 24(16):. PubMed ID: 31430908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
